{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:07:18Z","timestamp":1761293238827},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12957-015-0456-2","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T15:14:21Z","timestamp":1423667661000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic value of HLA class I expression in patients with colorectal cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Yuji","family":"Iwayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Tsuruma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Furuhata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0140-6736(05)17706-X","volume":"365","author":"J Weitz","year":"2005","unstructured":"Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153\u201365.","journal-title":"Lancet"},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1349-7006.2004.tb03167.x","volume":"95","author":"S Onogawa","year":"2004","unstructured":"Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 2004;95:32\u20139.","journal-title":"Cancer Sci"},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1179\/joc.2007.19.2.115","volume":"19","author":"J Wils","year":"2007","unstructured":"Wils J. Adjuvant treatment of colon cancer: past, present and future. J Chemotherapy. 2007;19:115\u201322.","journal-title":"J Chemotherapy"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet. 2007;370:2020\u20139.","journal-title":"Lancet"},{"key":"456_CR5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.1999.17.5.1356","volume":"17","author":"International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators","year":"1999","unstructured":"International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","volume":"29","author":"ES O\u2019Connor","year":"2011","unstructured":"O\u2019Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381\u20138.","journal-title":"J Clin Oncol"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3322\/canjclin.57.3.168","volume":"57","author":"BM Wolpin","year":"2007","unstructured":"Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168\u201385.","journal-title":"CA Cancer J Clin"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelus B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479\u2013516.","journal-title":"Ann Oncol"},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","volume":"74","author":"FM Marincola","year":"2000","unstructured":"Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181\u2013273.","journal-title":"Adv Immunol"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.2001.0404","volume":"12","author":"B Seliger","year":"2002","unstructured":"Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3\u201313.","journal-title":"Semin Cancer Biol"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2004.11.064","volume":"228","author":"L Raffaghello","year":"2005","unstructured":"Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005;228:155\u201361.","journal-title":"Cancer Lett"},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.4049\/jimmunol.176.6.3402","volume":"176","author":"A Lopez-Albaitero","year":"2006","unstructured":"Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402\u20139.","journal-title":"J Immunol"},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1440-1827.2012.02789.x","volume":"62","author":"T Torigoe","year":"2012","unstructured":"Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 2012;62:303\u20138.","journal-title":"Pathol Int"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00595-007-3689-z","volume":"38","author":"F Hata","year":"2008","unstructured":"Hata F, Sasaki K, Hirata K, Yamamitsu S, Shirasaka T. Efficacy of a continuous versus infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial. Surg Today. 2008;38:623\u201332.","journal-title":"Surg Today"},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","volume":"97","author":"T Tsukahara","year":"2006","unstructured":"Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97:1374\u201380.","journal-title":"Cancer Sci"},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0009-8981(98)00146-6","volume":"278","author":"T Le Neel","year":"1998","unstructured":"Le Neel T, Moreau A, Laboisse C, Truchaud A. Comparative evaluation of automated systems in immunohistochemistry. Clin Chim Acta. 1998;278:185\u201392.","journal-title":"Clin Chim Acta"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.juro.2006.11.082","volume":"177","author":"H Kitamura","year":"2007","unstructured":"Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007;177:1269\u201372.","journal-title":"J Urol"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/j.1349-7006.2009.01329.x","volume":"100","author":"I Homma","year":"2009","unstructured":"Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, et al. Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci. 2009;100:2331\u20134.","journal-title":"Cancer Sci"},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","volume":"12","author":"H Kitamura","year":"2006","unstructured":"Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, et al. Effects of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Cancer Res. 2006;12:4641\u20134.","journal-title":"Clin Cancer Res"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/jso.21829","volume":"103","author":"H Yabe","year":"2011","unstructured":"Yabe H, Tsukahara T, Kawaguchi S, Wada T, Torigoe T, Sato N, et al. Prognostic significance of HLA class I expression in Ewing\u2019s sarcoma family of tumors. J Surg Oncol. 2011;103:380\u20135.","journal-title":"J Surg Oncol"},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ijc.21163","volume":"117","author":"Z Madjd","year":"2005","unstructured":"Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005;117:248\u201355.","journal-title":"Int J Cancer"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.21303","volume":"118","author":"NF Watson","year":"2006","unstructured":"Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis O, Scholefild JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118:6\u201310.","journal-title":"Int J Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12957-015-0456-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0456-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-015-0456-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:07:25Z","timestamp":1630570045000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-015-0456-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1186\/s12957-015-0456-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]},"assertion":[{"value":"31 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"36"}}